Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | CPB1 | P15086 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19402272 | 0.98 | KDM4C (0.42) | KDM4CCPB2CYP2B6PHF8WDR5 | |
| Hydrochloric Acid SCHEMBL23389293 | 0.73 | KDM4C (0.44) | KDM4CCPB2CYP2B6PHF8WDR5 | |
| SCHEMBL29910399 | 0.70 | CYP2B6 (0.47) | KDM4CCPB2CYP2B6PHF8WDR5 | |
| Hydrochloric Acid SCHEMBL23389331 | 0.70 | CPB2 (0.43) | KDM4CCPB2CYP2B6PHF8WDR5 | |
| SCHEMBL22833771 | 0.68 | KDM4C (0.42) | KDM4CCPB2CYP2B6PHF8WDR5 | |
| SCHEMBL19402036 | 0.68 | PHF8 (0.42) | KDM4CCPB2CYP2B6PHF8NPC1 | |
| SCHEMBL16972901 | 0.67 | PHF8 (0.45) | KDM4CCPB2CYP2B6PHF8WDR5 | |
| SCHEMBL22854663 | 0.67 | PHF8 (0.45) | KDM4CCPB2CYP2B6PHF8WDR5 | |
| Hydrochloric Acid SCHEMBL22833576 | 0.66 | PHF8 (0.44) | KDM4CCPB2CYP2B6PHF8WDR5 | |
| Hydrochloric Acid SCHEMBL23389343 | 0.66 | PHF8 (0.44) | KDM4CCPB2CYP2B6PHF8WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434674-B1 | ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3434674-B1 | ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-18 | — | — | US | disclosed |
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-18 | — | — | US | disclosed |
| EP-3434674-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| EP-3434674-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162133-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | 上海海和药物研究开发有限公司 | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | IDH1, IDH3A, IDH2 | KDM4C 1044/4885CPB2 3742/4885CYP2B6 555/4885 |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | IDH1, IDH3A, IDH2 | KDM4C 1044/4885CPB2 3742/4885CYP2B6 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.